It’s normal to have lots of questions when you start a new prescription medication. Whether you can drink alcohol might be at ...
People with a high body weight living in England can now access subsidised weight-loss drugs to treat their obesity.
Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...
Last week, the US Food and Drug Administration (FDA) announced the end of a years-long shortage of semaglutide injection products — a ...
The popular medications may still suffer from local shortages, but FDA is confident that the national supply will remain ...
New diabetes medications are pressuring Medicare Part D financially as they drive up prescription drug costs amid rising ...
Hims & Hers stock drops 26% as FDA resolves semaglutide shortage, threatening GLP-1 revenue. Click here to find out why HIMS ...
Lars Fruergaard Jørgensen might not be a household name, but his company’s drug Ozempic is. And its success has thrust him — ...
Despite the continued success of GLP-1 drugs Ozempic and Wegovy, Novo Nordisk CEO Lars Fruergaard Jørgensen took a slight pay cut in 2024. He received 57.1 million Danish kroner (DKK) – $8 million – ...
The United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) reports an increase in deaths linked to ...
14h
Hosted on MSNMore Data Assuage Suicide Concerns With GLP-1 AgentsRisk of suicidality wasn't higher for type 2 diabetes patients starting on GLP-1 receptor agonists than for those on two other popular classes of diabetes drugs, a U.K. cohort study found. In fully ...
Lars Fruergaard Jørgensen is a CEO who didn't want to be CEO but under his tenure Novo Nordisk, which makes Ozempic, has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results